Article
Oncology
Tingmang Yan, Dapeng Zhou, Youwei Shi, Di Cui, Juntao Jiang, Bangmin Han, Shujie Xia, Zhou Wang, Haitao Liu, Wenhuan Guo, Yifeng Jing
Summary: The study revealed that AR stabilizes Siah2 protein by blocking its E3 ubiquitin ligase activity, while ADT reduces Siah2 protein expression but enhances its E3 ligase activity in PCa cells. The combination of ADT with Vit K3 shows promising results in delaying the occurrence of CRPC and inhibiting tumor growth.
FRONTIERS IN ONCOLOGY
(2021)
Article
Medicine, General & Internal
Mallika Marar, Qi Long, Ronac Mamtani, Vivek Narayan, Neha Vapiwala, Ravi B. Parikh
Summary: This study investigated the differences in outcomes between African American and non-Hispanic White men with metastatic castration-resistant prostate cancer (mCRPC) who received first-line abiraterone therapy. The results showed that African American men had a higher overall survival when receiving first-line abiraterone compared to non-Hispanic White men. However, there was a difference in outcomes between the two groups for first-line enzalutamide treatment.
Editorial Material
Oncology
Maree Pechlivanis, Bethany K. Campbell, Christopher M. Hovens, Niall M. Corcoran
Summary: Prostate cancer is a major cause of cancer deaths in men. High-risk prostate cancer patients often receive neoadjuvant androgen deprivation therapy, but this treatment may lead to resistance. The mechanisms behind this resistance are still poorly understood and further research is needed to address this issue.
Article
Oncology
Fatima Karzai, Stephanie M. Walker, Scott Wilkinson, Ravi A. Madan, Joanna H. Shih, Maria J. Merino, Stephanie A. Harmon, David J. VanderWeele, Lisa M. Cordes, Nicole Carrabba, John R. Bright, Nicolas T. Terrigino, Guinevere Chun, Marijo Bilusic, Anna Couvillon, Amy Hankin, Monique N. Williams, Rosina T. Lis, Huihui Ye, Peter L. Choyke, James L. Gulley, Adam G. Sowalsky, Baris Turkbey, Peter A. Pinto, William L. Dahut
Summary: For patients with localized intermediate- or high-risk prostate cancer, baseline mpMRI can help predict pathologic response, with low relative tumor burden at initial scan being most predictive of minimal residual disease or pathologic complete response. Tailoring patient selection based on these metrics may lead to improved outcomes in high-risk disease.
CLINICAL CANCER RESEARCH
(2021)
Article
Biochemistry & Molecular Biology
Ulrich Sommer, Tiziana Siciliano, Celina Ebersbach, Alicia-Marie K. Beier, Matthias B. Stope, Korinna Joehrens, Gustavo B. Baretton, Angelika Borkowetz, Christian Thomas, Holger H. H. Erb
Summary: PSMA protein plays an important role in the diagnosis and treatment of prostate cancer, and the activation and inhibition of androgen receptor (AR) can affect PSMA protein levels. This study found that AR activation and inhibition affect PSMA protein levels through a possible non-canonical mechanism, and low PSMA expression rates may be necessary to increase PSMA protein through androgen deprivation.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Biochemistry & Molecular Biology
David Ka-Wai Leung, Peter Ka-Fung Chiu, Chi-Fai Ng, Jeremy Yuen-Chun Teoh
Summary: The management of castration-resistant prostate cancer has seen significant progress, with three novel hormonal agents showing survival benefits in non-metastatic patients and a wider range of management options being investigated for metastatic disease.
Review
Multidisciplinary Sciences
Yash B. Shah, Amy L. Shaver, William Kevin Kelly, Grace Lu-Yao
Summary: Abiraterone acetate and enzalutamide are commonly used in prostate cancer therapy, but their toxicities and interactions with patient comorbidities are unclear. Analyzing the differential patient outcomes between these two drugs can provide information for future research and clinical decision-making.
Review
Biochemistry & Molecular Biology
Tae Jin Kim, Young Hwa Lee, Kyo Chul Koo
Summary: The androgen receptor (AR) plays a crucial role in the development and progression of prostate cancer (PCa), and treatment for hormone-sensitive prostate cancer (HSPC) relies heavily on androgen deprivation therapy (ADT). Despite most patients progressing to castration-resistant prostate cancer (CRPC), studies suggest that manipulating alternative molecular pathways can help improve current treatments and develop novel therapies for CRPC management.
Article
Medicine, General & Internal
Shabbir M. H. Alibhai, Henriette Breunis, Gregory Feng, Narhari Timilshina, Aaron Hansen, Padraig Warde, Richard Gregg, Anthony Joshua, Neil Fleshner, George Tomlinson, Urban Emmenegger
Summary: This study longitudinally examined cognitive function in older men with metastatic castration-resistant prostate cancer undergoing treatment with docetaxel, abiraterone, enzalutamide, and radium Ra 223. The findings suggest that most older men do not experience significant cognitive decline in attention, executive function, and global cognition regardless of the treatment used.
Review
Biochemistry & Molecular Biology
Sooraj Kakkat, Paramahansa Pramanik, Seema Singh, Ajay Pratap Singh, Chandrani Sarkar, Debanjan Chakroborty
Summary: Cardiovascular diseases (CVDs) and complications are commonly observed in patients with prostate cancer (PCa) and can impact their clinical management. Androgen deprivation therapy (ADT), the main treatment for PCa, has been shown to increase cardiovascular risks and metabolic syndromes. There is emerging evidence of a molecular link between PCa and CVDs, but it remains to be fully understood. This article explores the connection between PCa and CVDs, utilizing a comprehensive gene expression study and biological pathway analysis.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Medicine, General & Internal
Gerhardt Attard, Laura Murphy, Noel W. Clarke, William Cross, Robert J. Jones, Christopher C. Parker, Silke Gillessen, Adrian Cook, Chris Brawley, Claire L. Amos, Nafisah Atako, Cheryl Pugh, Michelle Buckner, Simon Chowdhury, Zafar Malik, J. Martin Russell, Clare Gilson, Hannah Rush, Jo Bowen, Anna Lydon, Ian Pedley, Joe M. O'Sullivan, Alison Birtle, Joanna Gale, Narayanan Srihari, Carys Thomas, Jacob Tanguay, John Wagstaff, Prantik Das, Emma Gray, Mymoona Alzoueb, Omi Parikh, Angus Robinson, Isabel Syndikus, James Wylie, Anjali Zarkar, George Thalmann, Johann S. de Bono, David P. Dearnaley, Malcolm D. Mason, Duncan Gilbert, Ruth E. Langley, Robin Millman, David Matheson, Matthew R. Sydes, Louise C. Brown, Mahesh K. B. Parmar, Nicholas D. James
Summary: The combination therapy of abiraterone acetate with prednisolone showed significantly higher rates of metastasis-free survival compared with ADT alone in men with high-risk non-metastatic prostate cancer. This combination therapy may be considered a new standard treatment for this patient population.
Review
Oncology
Thi Khanh Le, Quang Hieu Duong, Virginie Baylot, Christelle Fargette, Michael Baboudjian, Laurence Colleaux, David Taieb, Palma Rocchi
Summary: Castration-resistant prostate cancer remains a significant medical challenge, and it is important to understand the underlying mechanisms of resistance and develop new treatment approaches. This review provides an overview of the mechanisms contributing to CRPC progression and discusses current treatment options.
Review
Biochemistry & Molecular Biology
Ivan Henriquez, Mack I. I. I. I. I. I. Roach, Todd M. Morgan, Alberto Bossi, Junior A. Gomez, Oscar Abuchaibe, Felipe Counago
Summary: mCRPC is a complex disease with a wide range of molecular tumor behavior and high risk of progression, making early detection and treatment crucial. Treatment options have improved significantly in recent years, but clinicians find it challenging to keep up with the rapidly changing therapeutic landscape.
Article
Oncology
Yuki Yoshikawa, Konrad H. Stopsack, Xin Victoria Wang, Yu-Hui Chen, Ying Z. Mazzu, Foster Burton, Goutam Chakraborty, Sai Harisha Rajanala, Rahim Hirani, Subhiksha Nandakumar, Gwo-Shu Mary Lee, David Frank, Elai Davicioni, Glenn Liu, Michael A. Carducci, Haruhito Azuma, Philip W. Kantoff, Christopher J. Sweeney
Summary: Loss of the histone demethylase KDM5D leads to increased resistance of prostate cancer cells to androgen deprivation therapy and docetaxel. MYBL2 is identified as a downstream driver of KDM5D effect. Lower levels of MYBL2 are associated with better clinical outcomes.
MOLECULAR ONCOLOGY
(2022)
Article
Multidisciplinary Sciences
Sheng-Feng Lin, Hsiu-Chen Lin, Mei-Yu Lee, Joseph Jordan Keller, Li-Hsuan Wang
Summary: This study found a decreased risk of atopic diseases in patients with prostate cancer treated with GnRH analogues. Further studies are warranted to verify the association between testosterone levels and atopic diseases.